All In Biotech

Drug Trial Radar · NCT00068042

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

Last checked: Nov 20, 2026Latest source record: Apr 7, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Apr 2003

Primary completion

Not stated

Study completion May 2006

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 8, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Conditions

  • Acromegaly

Interventions

  • PegvisomantDrug

  • Sandostatin LARDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with normal IGF-1 concentration at Final Visit (Week 52)

Locations

55 sites in 13 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Ann Arbor, Michigan

  • Pfizer Investigational Site

    Ann Arbor, Michigan

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Chapel Hill, North Carolina

  • Pfizer Investigational Site

    Cleveland, Ohio

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania

  • Pfizer Investigational Site

    Houston, Texas

  • Pfizer Investigational Site

    Charlottesville, Virginia

  • Pfizer Investigational Site

    Darlinghurst, New South Wales, Australia

  • Pfizer Investigational Site

    Westmead, New South Wales, Australia

  • Pfizer Investigational Site

    Fitzroy, Victoria, Australia

  • Pfizer Investigational Site

    Heidelberg, Victoria, Australia

  • Pfizer Investigational Site

    Curitiba, Paraná, Brazil

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Pfizer Investigational Site

    São Paulo, São Paulo, Brazil

  • Pfizer Investigational Site

    Edmonton, Alberta, Canada

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    Montreal, Quebec, Canada

  • Pfizer Investigational Site

    Le Kremlin-Bicêtre, France

  • Pfizer Investigational Site

    Pessac, France

  • Pfizer Investigational Site

    Berlin, Germany

  • Pfizer Investigational Site

    Dresden, Germany

  • Pfizer Investigational Site

    Essen, Germany

  • Pfizer Investigational Site

    Hamburg, Germany

  • Pfizer Investigational Site

    Heidelberg, Germany

  • Pfizer Investigational Site

    Marburg, Germany

  • Pfizer Investigational Site

    Piraeus, Greece

  • Pfizer Investigational Site

    Athens, Attika/Greece, Greece

  • Pfizer Investigational Site

    Cork, Ireland

  • Pfizer Investigational Site

    Dublin, Ireland

  • Pfizer Investigational Site

    Genova, Italy

  • Pfizer Investigational Site

    Milan, Italy

  • Pfizer Investigational Site

    Naples, Italy

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.